Skip to main content
logo
Aptevo Therapeutics logo
Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.735
+0.005 (0.29%)
Oct 14, 2026, 10:22 AM EDT - Market open

Aptevo Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----3.1112.29
Revenue Growth
-----74.67%185.26%
Gross Profit
-----14.77-6.7
Operating Income
-26.89-26.31-24.6-28.88-28.64-21.4
Net Income
-26.51-25.97-24.13-17.418.03-28.46
Earnings Per Share
-29.72-82.30----
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
9.821.628.7116.922.6445.04
Total Debt
4.214.635.45.49.9616.72
Net Cash (Debt)
5.5916.993.3211.5112.6828.33
Net Cash Growth
26.97%412.21%-71.17%-9.24%-55.24%125.46%
Net Cash Per Share
6.2753.85----

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-25.34-25.59-23.79-11.73-21.02-21.68
Capital Expenditures
-----0.03-0.71
Free Cash Flow
-25.34-25.59-23.79-11.73-21.05-22.39
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------54.52%
Operating Margin
-----919.75%-174.10%
Pretax Margin
----225.24%-239.25%
Profit Margin
----257.77%-231.51%
FCF Margin
-----676.01%-182.17%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----1.36-
Forward PE
-160.84160.84160.84160.84160.84
PS Ratio
----3.493.00